University of Nebraska Medical Center at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
University of Nebraska Medical Center takes part in 2 sessions at ASH 2026 in New Orleans. Its program centres on lymphoma, including primary lymphoma of the brain and spinal cord and diffuse large B-cell lymphoma. It covers molecular pathways and emerging therapies in primary CNS lymphoma, and biomarker-driven management of DLBCL.
| Organization | ASH 2026 Attendance |
|---|---|
Nebraska's public academic health sciences center in Omaha, partnered with the Nebraska Medicine health system. | Symposium Fri Dec 11 3:00pm–6:00pm Live Tumor Board: Advancing Clinical Competence in Primary CNS Lymphoma — Navigating Molecular Pathways and Emerging Therapies Treating primary central nervous system lymphoma, from methotrexate-based induction and consolidation choices to new drugs aimed at its signaling mutations. Symposium Fri Dec 11 11:00am–2:00pm Medical Crossfire®: Redefining DLBCL — How Biomarker- and Mechanism-Driven Strategies Are Reshaping Management Across the Disease Continuum Using molecular subtypes of diffuse large B-cell lymphoma to choose frontline treatment among polatuzumab regimens, bispecific antibodies, and CAR-T. |
Instantly find 20 buyers from University of Nebraska Medical Center
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction